These strategies, when employed in conjunction with existing treatments such as radiotherapy and targeted drug delivery systems, offer the potential for more comprehensive and durable cancer therapies by addressing both tumor survival mechanisms and NFE2L2-driven resistance pathways[139,140]. This evidence concerns the gene NFE2L2 and neoplasm.